Mark Flather | Vice President, Investor Relations |
Shawn Singh | Chief Executive Officer |
Jerry Dotson | Chief Financial Officer |
Mark Smith | Chief Medical Officer |
Andrew Tsai | Jefferies |
Lachlan Hanbury-Brown | William Blair |
Luke Herrmann | Baird |
Joanne Lee | Maxim Group |
Greetings and welcome to VistaGen Therapeutics’ Third Quarter of Fiscal Year 2022 Results Conference Call. [Operator instructions] And please note that this conference is being recorded. I will now turn the conference over to your host Mark Flather, Vice President of Investor Relations. Thank you.
You may begin.